NCT02684370 - BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter

Enrollment

560

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

September 30, 2017

Conditions

Psoriasis

Interventions

DRUG

risankizumab

Risankizumab administered by subcutaneous (SC) injection

DRUG

placebo for risankizumab

Placebo for risankizumab administered by subcutaneous (SC) injection

DRUG

ustekinumab

Ustekinumab administered by subcutaneous (SC) injection

DRUG

placebo for ustekinumab

Placebo for ustekinumab administered by subcutaneous (SC) injection